[go: up one dir, main page]

NO20071142L - Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor - Google Patents

Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor

Info

Publication number
NO20071142L
NO20071142L NO20071142A NO20071142A NO20071142L NO 20071142 L NO20071142 L NO 20071142L NO 20071142 A NO20071142 A NO 20071142A NO 20071142 A NO20071142 A NO 20071142A NO 20071142 L NO20071142 L NO 20071142L
Authority
NO
Norway
Prior art keywords
renin inhibitor
methods
improved bioavailability
inhibitor
bioavailability
Prior art date
Application number
NO20071142A
Other languages
English (en)
Inventor
Gian T Camenisch
Gerhard Gross
Isabel Ottinger
Daniel Wasmuth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071142(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20071142L publication Critical patent/NO20071142L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for å forbedre biotilgjengeligheten for en renininhibitor, fortrinnsvis et d-amino-?-hydroksy-?-aryl-alkansyreamidderivat. Fremgangsmåten omfatter ko-administrering til et pattedyr, særlig et menneske, som trenger slik behandling, av en kombinasjon av en renininhibitor, eller et farmasøytisk akseptabelt salt derav, og en effluksproteininhibitor.
NO20071142A 2004-08-03 2007-02-28 Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor NO20071142L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59870004P 2004-08-03 2004-08-03
PCT/EP2005/008369 WO2006013094A1 (en) 2004-08-03 2005-08-02 Methods for improving bioavailability of a renin inhibitor

Publications (1)

Publication Number Publication Date
NO20071142L true NO20071142L (no) 2007-04-26

Family

ID=35056890

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071142A NO20071142L (no) 2004-08-03 2007-02-28 Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor

Country Status (31)

Country Link
US (1) US7709532B2 (no)
EP (2) EP2191823A1 (no)
JP (1) JP5134366B2 (no)
KR (1) KR20070040384A (no)
CN (1) CN1993116B (no)
AR (1) AR050043A1 (no)
AT (1) ATE449601T1 (no)
AU (1) AU2005268844B2 (no)
BR (1) BRPI0514021A (no)
CA (1) CA2572743C (no)
CY (1) CY1109826T1 (no)
DE (1) DE602005017905D1 (no)
DK (1) DK1776099T3 (no)
EC (1) ECSP077169A (no)
ES (1) ES2335597T3 (no)
HR (1) HRP20100064T1 (no)
IL (1) IL180678A (no)
MA (1) MA28821B1 (no)
MX (1) MX2007001339A (no)
MY (1) MY142180A (no)
NO (1) NO20071142L (no)
NZ (1) NZ552903A (no)
PE (1) PE20060416A1 (no)
PL (1) PL1776099T3 (no)
PT (1) PT1776099E (no)
RU (1) RU2404758C2 (no)
SI (1) SI1776099T1 (no)
TN (1) TNSN07038A1 (no)
TW (1) TW200616610A (no)
WO (1) WO2006013094A1 (no)
ZA (1) ZA200610639B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
EP1927350A1 (en) * 2006-11-24 2008-06-04 Novartis AG Methods for improving bioavailability of a renin inhibitor
CA2769392A1 (en) 2009-07-31 2011-02-03 Sandoz Ag Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method
WO2012010651A2 (en) 2010-07-23 2012-01-26 Sandoz Ag Method for the preparation of omega-amino-alkaneamides and omega-amino-alkanethioamides as well as intermediates of this method
WO2014168255A1 (ja) * 2013-04-12 2014-10-16 国立大学法人京都大学 巨核球の成熟化促進物質
US10201552B2 (en) 2013-09-05 2019-02-12 Howard University Method of increasing the bioavailability of an HIV drug
JP6029621B2 (ja) * 2014-07-14 2016-11-24 ヤマサ醤油株式会社 血漿レニン活性の測定法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2224227A1 (en) 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
JP4295913B2 (ja) * 1997-08-14 2009-07-15 アベンティス・ファーマスーティカルズ・インコーポレイテツド フェキソフェナジンおよびその誘導体のバイオアベイラビリティーを強化する方法
HUP0203303A3 (en) * 1999-10-27 2005-01-28 Baker Norton Pharma Compositions for administering taxanes orally to human patients
CA2398567A1 (en) * 2000-02-11 2001-08-16 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
US6683169B2 (en) * 2000-05-31 2004-01-27 Rutgers, The State University Of New Jersey Nucleic acid encoding the human peptide histidine transporter 1 and methods of use thereof
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
US20030198619A1 (en) 2001-12-19 2003-10-23 Dong Liang C. Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP1501546B1 (de) * 2002-05-03 2012-10-10 Hexal AG Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
AU2003255527A1 (en) 2002-06-28 2004-01-19 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders

Also Published As

Publication number Publication date
EP2191823A1 (en) 2010-06-02
EP1776099B1 (en) 2009-11-25
MX2007001339A (es) 2007-03-27
AU2005268844A1 (en) 2006-02-09
ECSP077169A (es) 2007-02-28
IL180678A0 (en) 2008-03-20
CN1993116A (zh) 2007-07-04
NZ552903A (en) 2010-09-30
RU2404758C2 (ru) 2010-11-27
IL180678A (en) 2011-04-28
PE20060416A1 (es) 2006-06-09
BRPI0514021A (pt) 2008-05-27
CA2572743A1 (en) 2006-02-09
US20080108703A1 (en) 2008-05-08
CN1993116B (zh) 2011-04-13
JP2008508340A (ja) 2008-03-21
ZA200610639B (en) 2008-05-28
JP5134366B2 (ja) 2013-01-30
RU2007107850A (ru) 2008-09-10
PL1776099T3 (pl) 2010-05-31
MY142180A (en) 2010-10-15
HRP20100064T1 (hr) 2010-03-31
PT1776099E (pt) 2010-01-06
TNSN07038A1 (en) 2008-06-02
AU2005268844B2 (en) 2009-03-05
MA28821B1 (fr) 2007-08-01
DK1776099T3 (da) 2010-03-01
CA2572743C (en) 2012-12-04
AR050043A1 (es) 2006-09-20
DE602005017905D1 (de) 2010-01-07
KR20070040384A (ko) 2007-04-16
ES2335597T3 (es) 2010-03-30
US7709532B2 (en) 2010-05-04
WO2006013094A1 (en) 2006-02-09
ATE449601T1 (de) 2009-12-15
SI1776099T1 (sl) 2010-03-31
TW200616610A (en) 2006-06-01
CY1109826T1 (el) 2014-09-10
EP1776099A1 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
NO20071142L (no) Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
NO20073650L (no) Stilbenderivater og deres anvendelse til binding og avbilding av amyloidplakker
NO20055496D0 (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
BRPI0512193B8 (pt) composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
CY1123426T1 (el) Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20044562L (no) Fremgangsmater for behandling av tarmslyng
WO2006059245A3 (en) Compounds for the treatment of cns and amyloid associated diseases
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
CY1112451T1 (el) Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
WO2006014664A3 (en) Cyclopentylamine and cyclohexylamine derivatives as nk-1/ssri antagonists
MX2009005247A (es) Metodos para mejorar la biodisponibilidad de un inhibidor de renina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application